299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02498535 (ClinicalTrials.gov)	February 22, 2017	12/7/2015	Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients	Prospective, Randomized, Placebo Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients	Cystic Fibrosis	Drug: Nitric Oxide 160 ppm	Novoteris, LLC	Cystic Fibrosis Foundation;Mallinckrodt	Terminated	18 Years	N/A	All	49	Phase 2	United States;Canada
2	NCT01958944 (ClinicalTrials.gov)	December 2013	6/10/2013	Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis	Phase II Prospective, Open Labeled, Multi-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: Nitric oxide	Advanced Inhalation Therapies Ltd	Soroka University Medical Center;Schneider Children's Medical Center, Israel	Completed	10 Years	N/A	Both	9	Phase 1/Phase 2	Israel
3	NCT02295566 (ClinicalTrials.gov)	May 2011	20/8/2014	RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study	RATNO (Reducing Antibiotic Tolerance Using NO) Reducing Antibiotic Tolerance Using Low Dose Nitric Oxide in Cystic Fibrosis - a Phase 2 Pilot Study	Cystic Fibrosis	Drug: Nitric Oxide;Drug: Control	University Hospital Southampton NHS Foundation Trust.	University of Southampton	Completed	12 Years	N/A	Both	12	Phase 2	United Kingdom
4	EUCTR2010-023529-39-GB (EUCTR)	18/02/2011	31/12/2010	Reducing antibiotic tolerance using low dose nitric oxide in cystic fibrosis – a phase 2 pilot study - RATNO (Reducing Antibiotic Tolerance using Nitric Oxide in CF) v 1.0	Reducing antibiotic tolerance using low dose nitric oxide in cystic fibrosis – a phase 2 pilot study - RATNO (Reducing Antibiotic Tolerance using Nitric Oxide in CF) v 1.0	Cystic Fibrosis	Trade Name: INOmax 400ppm mol/mol inhalation gas Product Name: Nitric Oxide Product Code: NO	Southampton University Hopsitals NHS Trust	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	United Kingdom
5	NCT00570349 (ClinicalTrials.gov)	July 2004	6/12/2007	Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Nitric Oxide for Inhalation;Drug: Nitrogen	Mallinckrodt	NULL	Completed	12 Years	N/A	All	18	Phase 1/Phase 2	United States